NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CRBP

Corbus Pharmaceuticals Holdings Inc

Jul 11 • 04:00PM ET

8.27

Dollar change -0.09
Percentage change -1.08	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN GILD NBIX INCY EXEL FOLD NKTR PBYI XOMA

| Held by: VTI VXF SCHA VTWO IWC SCHB VTWG VTWV MSSM RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.23	Insider Own	12.59%	Shs Outstand	12.23M	Perf Week	7.26%
Market Cap	101.20M	Forward P/E	-	EPS next Y	-4.49	Insider Trans	-1.31%	Shs Float	10.70M	Perf Month	-10.50%
Enterprise Value	-29.02M	PEG	-	EPS next Q	-1.50	Inst Own	82.45%	Short Float	14.42%	Perf Quarter	45.86%
Income	-50.29M	P/S	-	EPS this Y	-54.26%	Inst Trans	-8.53%	Short Ratio	9.35	Perf Half Y	-34.37%
Sales	0.00M	P/B	0.80	EPS next Y	20.82%	ROA	-37.86%	Short Interest	1.54M	Perf YTD	-29.92%
Book/sh	10.39	P/C	0.76	EPS next 5Y	-12.66%	ROE	-44.89%	52W High	61.90 -86.64%	Perf Year	-83.81%
Cash/sh	10.87	P/FCF	-	EPS past 3/5Y	30.83% 35.71%	ROIC	-39.19%	52W Low	4.64 78.23%	Perf 3Y	-0.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.99% 6.62%	Perf 5Y	-96.51%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	39.37%	Oper. Margin	-	ATR (14)	0.53	Perf 10Y	-90.93%
Dividend Ex-Date	-	Quick Ratio	11.82	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.82	EPS Q/Q	-67.62%	SMA20	2.82%	Beta	3.19	Target Price	41.62
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	6.18%	Rel Volume	0.50	Prev Close	8.36
Employees	28	LT Debt/Eq	0.01	Earnings	May 06 BMO	SMA200	-26.08%	Avg Volume	165.03K	Price	8.27
IPO	Oct 27, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.62% -	Trades		Volume	82,304	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform	$85
Jul-22-24	Resumed	H.C. Wainwright	Buy	$80
Jun-26-24	Initiated	B. Riley Securities	Buy	$85
Jun-03-24	Reiterated	Oppenheimer	Outperform	$60 → $80
May-13-24	Initiated	RBC Capital Mkts	Outperform	$77
Mar-06-24	Upgrade	Jefferies	Hold → Buy	$4 → $46
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral	$40 → $3
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	Jefferies	Buy → Hold	$18 → $2.50
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy	$40
Jun-17-20	Initiated	BTIG Research	Buy	$22
Mar-26-20	Initiated	Nomura	Buy	$12
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform	$28
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight	$36 → $38
Dec-26-18	Initiated	H.C. Wainwright	Buy	$24
Dec-07-18	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Jun-30-25 08:00AM	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire) -6.76%
Jun-25-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab (GlobeNewswire) +8.92%
Jun-24-25 04:05PM	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks)
May-22-25 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +5.72%
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-08-25 08:00AM	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +8.48%
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-06-25 08:08AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance) -15.77%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-25 08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-18-25 09:55AM	Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? (Zacks)
Mar-28-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire)
Mar-20-25 09:35AM	After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
09:35AM	Loading…
Mar-19-25 09:35AM	After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-13-25 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know (Zacks) -7.09%
Mar-11-25 08:17AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-25-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 01:17PM	Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate (Benzinga) -10.23%
07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 (GlobeNewswire)
Feb-11-25 07:30AM	Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU (GlobeNewswire) -10.22%
Jan-28-25 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 (GlobeNewswire)
Jan-06-25 08:00AM	Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-04-24 12:31PM	Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer (GlobeNewswire) -6.11%
Nov-26-24 06:54AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
08:00AM	Loading…
Nov-21-24 08:00AM	Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 07:28AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 04:10PM	Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat (Investor's Business Daily) +8.22%
07:00AM	Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-16-24 08:00AM	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) (GlobeNewswire)
Oct-15-24 07:02PM	Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals (GuruFocus.com)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc (GuruFocus.com)
Oct-03-24 05:07AM	Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit (GlobeNewswire)
Sep-24-24 09:41PM	Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals (GuruFocus.com) +16.41%
Sep-20-24 03:18PM	Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players (Benzinga) -62.26%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-05-24 08:00AM	Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference (GlobeNewswire) -8.32%
Sep-04-24 07:29PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:03PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-26-24 09:55AM	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct) +7.45%
Aug-20-24 08:00AM	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung (GlobeNewswire)
Aug-09-24 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why (Zacks) +5.54%
09:55AM	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade (Zacks)
Aug-06-24 08:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-24 08:50AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August (GlobeNewswire) +7.13%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace) +9.17%
Jun-30-24 10:13AM	Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
Jun-01-24 10:00AM	SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 (GlobeNewswire)
May-30-24 08:00AM	Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-23-24 05:05PM	Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting (GlobeNewswire) -7.96% +8.80%
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace) +7.89%
May-09-24 08:00AM	Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 01:52PM	CRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
08:17AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 02:06PM	How the Medical Industry Could Produce the Biggest AI Stock Winners (InvestorPlace)
May-01-24 08:00AM	Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum (GlobeNewswire)
Apr-24-24 04:05PM	Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting (GlobeNewswire) -5.83% -5.74%
Apr-19-24 02:30PM	These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? (InvestorPlace) +7.42%
Apr-16-24 08:50AM	Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength (Zacks)
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Apr-02-24 08:00AM	Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (GlobeNewswire)
Mar-15-24 08:50AM	What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing' (Zacks)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
Mar-12-24 08:21AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +16.46%
08:00AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit (GlobeNewswire)
Feb-28-24 08:00AM	Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer (GlobeNewswire) +7.40%
Feb-06-24 09:50AM	Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 04:01PM	Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-31-24 09:19AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) +5.29%
Jan-30-24 06:55PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire) +35.12%
Jan-29-24 06:57AM	Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate (News Direct) -36.86%
Jan-26-24 07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 (GlobeNewswire) +249.41%
Jan-23-24 08:00AM	Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU (GlobeNewswire)
Jan-09-24 08:00AM	Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti- v 8 monoclonal antibody (CRB-601) (GlobeNewswire)
Dec-18-23 08:00AM	Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU (GlobeNewswire)
Dec-01-23 09:40AM	Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-07-23 09:56AM	Corbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 Million (GuruFocus.com) -16.67%
08:11AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 08:00AM	Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti- V 8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting (GlobeNewswire)
Oct-17-23 08:00AM	Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023 (GlobeNewswire)
Oct-16-23 08:00AM	Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701 (GlobeNewswire)
Oct-03-23 08:00AM	Corbus Pharmaceuticals to Host Virtual 'Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023 (GlobeNewswire)
Sep-27-23 09:05AM	Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting (PR Newswire)
Sep-19-23 08:00AM	Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Aug-08-23 09:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jenkins John Kenneth	Director	May 30 '25	Sale	7.35	2,783	20,465	33	Jun 02 04:30 PM
Altmeyer Anne	Director	May 30 '25	Sale	7.25	1,392	10,096	1,391	Jun 02 04:30 PM
Smethurst Dominic	Chief Medical Officer	Mar 06 '25	Sale	6.78	6,393	43,330	70,807	Mar 07 04:30 PM
Smethurst Dominic	Officer	Mar 06 '25	Proposed Sale	6.84	6,393	43,728		Mar 06 04:03 PM
Moran Sean F.	Chief Financial Officer	Feb 14 '25	Sale	8.76	2,792	24,446	73,313	Feb 18 05:40 PM
Cohen Yuval	Chief Executive Officer	Feb 14 '25	Sale	8.76	7,134	62,465	138,187	Feb 18 05:40 PM
Moran Sean F.	Officer	Feb 14 '25	Proposed Sale	9.48	2,792	26,468		Feb 14 04:18 PM
Cohen Yuval	Officer	Feb 14 '25	Proposed Sale	9.48	7,134	67,630		Feb 14 04:16 PM
Cormorant Asset Management, LP	10% Owner	Sep 20 '24	Buy	20.01	350,000	7,003,761	2,375,000	Sep 24 04:04 PM
CATLIN AVERY W	Director	Sep 04 '24	Proposed Sale	56.43	888	50,109		Sep 04 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRBP

Corbus Pharmaceuticals Holdings Inc

Upgrade your FINVIZ experience